(Q36443080)

14 August 2017

1 reference

title

Proteasome inhibition: novel therapy for multiple myeloma (English)

1 reference

14 August 2017

2

Sagar Lonial

1 reference

14 August 2017

Jonathan L Kaufman

1

1 reference

14 August 2017

29 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

29

1 reference

14 August 2017

4

1 reference

14 August 2017

162-168

1 reference

Mechanisms underlying ubiquitination

14 August 2017

1 reference

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

21 January 2018

1 reference

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

21 January 2018

1 reference

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000091692

1 reference

14 August 2017

1 reference

PubMed ID

16601373